Hirvikoski P, Auvinen A, Servomaa K, Kiuru A, Rytömaa T, Makkonen K, Kosma V M
Department of Pathology, University of Kuopio, Finland.
Anticancer Res. 1999 Jan-Feb;19(1B):685-91.
The present study was undertaken to determine the prognostic significance of K-ras, p53 and bcl-2 in female rectal carcinoma.
The mutations in K-ras and p53 genes were analysed using SSCP and direct sequencing. The expression of K-ras, bcl-2 and p53 proteins was determined immunohistochemically.
Mutations of K-ras and p53 genes were detected in 12% and 38% of the tumours, respectively. The prevalence of K-ras overexpression was 67%. K-ras mutations were not associated with survival. However, more favourable survival was observed for patients with K-ras overexpression than with normal expression (adjusted hazard ratio from Cox model 0.4, 95% CI 0.2-0.8). Mutation or overexpression of p53 were not associated with survival.
It may be possible, that the mutations and protein overexpression of K-ras and p53 in female rectal carcinoma have different clinical impact on patient survival as suggested in previous studies concerning colorectal carcinoma of both sexes.
本研究旨在确定K-ras、p53和bcl-2在女性直肠癌中的预后意义。
采用单链构象多态性（SSCP）和直接测序法分析K-ras和p53基因的突变情况。采用免疫组织化学法检测K-ras、bcl-2和p53蛋白的表达。
分别在12%和38%的肿瘤中检测到K-ras和p53基因的突变。K-ras过表达的发生率为67%。K-ras突变与生存率无关。然而，与正常表达的患者相比，K-ras过表达的患者生存率更高（Cox模型调整后的风险比为0.4，95%置信区间为0.2-0.8）。p53的突变或过表达与生存率无关。
正如先前关于男女结肠癌的研究所表明的那样，女性直肠癌中K-ras和p53的突变及蛋白过表达可能对患者生存具有不同的临床影响。
